Sun Pharmaceutical Industries Limited appears to be a financially stable company with a strong gross margin of 79.56% and a decent profit margin of 20.79%. The company's return on equity (ROE) of 15.71% indicates efficient use of shareholder capital. However, the company's revenue and earnings growth rates are sluggish, and its debt-to-equity ratio of 3.26 is a concern. The company's valuation, with a trailing P/E of 36.48 and forward P/E of 50.85, seems relatively high. Overall, the company's financial health is decent, but it needs to address its growth concerns and high debt levels.